51ºÚÁϳԹÏÍø

ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
51ºÚÁϳԹÏÍø

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 51ºÚÁϳԹÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

51ºÚÁϳԹÏÍø Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Editorial   
  • Clin Pharmacol Biopharm,

Understanding Adverse Drug Reactions (ADRs): Risks, Impact, and Prevention Strategies

Lada Leyens*
Centre for Regulatory Science, Department of Health Information, Prasanna School of Public Health, Karnataka, India
*Corresponding Author : Lada Leyens, Centre for Regulatory Science, Department of Health Information, Prasanna School of Public Health, Karnataka, India, Email: lada67@gmail.com

Received Date: Jan 03, 2025 / Published Date: Jan 30, 2025

Abstract

Adverse drug reactions (ADRs) are a significant public health concern, affecting millions of patients worldwide and contributing to morbidity, mortality, and healthcare costs. ADRs are unintended and harmful effects that occur due to the use of medications, ranging from mild symptoms to severe reactions. This paper aims to explore the risks, impact, and prevention strategies associated with ADRs, emphasizing the factors that contribute to their occurrence, such as genetic predispositions, drug interactions, and underlying health conditions. It also examines the clinical, economic, and social burden of ADRs and outlines current strategies for reducing their occurrence, including pharmacovigilance, personalized medicine, and patient education. The paper concludes by discussing the need for continued research and improved clinical practices to mitigate the impact of ADRs.

Citation: Lada L (2025) Understanding Adverse Drug Reactions (ADRs): Risks, Impact, and Prevention Strategies Clin Pharmacol Biopharm, 14: 533.

Copyright: © 2025 Lada L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

International Conferences 2025-26
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top